EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer

Yingying Chen, Shiyu Liu, Xia Yin

American Journal of Cancer Research · 2025 · 15 (1) · 217-232

DOI: 10.62347/qtwj8918 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Cancer Research, 2025. Verfasst von Yingying Chen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University Chengdu, Sichuan, P. R. China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

BMI1PTC596cervical cancerimmunotherapytargeted therapy

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University Chengdu, Sichuan, P. R. China.
  • Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University Chengdu, Sichuan, P. R. China.

Zitieren

APA

Chen, Y., Liu, S., & Yin, X. (2025). Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer. American Journal of Cancer Research, 15(1), 217-232. https://doi.org/10.62347/qtwj8918

Vancouver

Chen Y, Liu S, Yin X. Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer. American Journal of Cancer Research. 2025;15(1):217-232. doi:10.62347/qtwj8918

BibTeX
@article{Chen2025,
  author = {Chen, Yingying and Liu, Shiyu and Yin, Xia},
  title = {Progress and prospects of the combination of BMI1-targeted therapy and immunotherapy in cervical cancer},
  journal = {American Journal of Cancer Research},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {217--232},
  doi = {10.62347/qtwj8918}
}
Kostenlos starten →